Spyre Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €0.00 +NaN% -€310.44M +13.9% N/A -€71.65M -68.7% N/A
    (estimated) €0.00 -100.0% -€272.67M +16.4% N/A -€228.59M +14.1% N/A
    (estimated) €119.41K +55.6% -€234.29M +18.1% -196,200.0% +620 pp -€200.27M +13.9% -167,714.3% +610 pp
    (estimated) €76.77K +0.0% -€198.40M +22.2% -258,444.4% -470 pp -€175.79M +8.5% -229,000.0% -180 pp
    (estimated) €76.77K +∞% -€162.33M -8.5% -211,455.6% -2.1K pp -€161.98M +20.6% -211,000.0% -2.1K pp
    €0.00 -100.0% -€177.43M -38.6% N/A -€134.26M +57.6% N/A
    €755.71K -62.0% -€288.97M +304.2% -38,238.1% -350 pp -€85.22M +24.7% -11,276.5% -78 pp
    €1.99M -87.6% -€71.49M +27.4% -3,598.8% -32 pp -€68.33M +50.7% -3,439.5% -32 pp
    €15.98M +∞% -€56.13M -18.7% -351.1% -3.5 pp -€45.33M -25.7% -283.6% -2.8 pp
    €0.00 +NaN% -€69.00M +3.4% N/A -€60.98M +11.4% N/A
    €0.00 -100.0% -€66.75M +76.5% N/A -€54.76M +102.1% N/A
    €3.32M -25.3% -€37.83M +62.8% -1,140.6% -6.2 pp -€27.10M +32.4% -817.2% -3.6 pp
    €4.44M +12.5% -€23.23M +25.5% -523.3% -0.54 pp -€20.47M +28.8% -461.0% -0.59 pp
    €3.95M -23.9% -€18.51M +92.1% -468.8% -2.8 pp -€15.89M +72.9% -402.5% -2.3 pp
    €5.19M +∞% -€9.63M +9.2% -185.6% -1.9 pp -€9.19M +50.6% -177.1% -1.8 pp
    €0.00 -€8.83M N/A -€6.10M N/A

    Notifications